MacroGenics
MGNX
135 hedge funds and large institutions have $375M invested in MacroGenics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 48 reducing their positions, and 27 closing their positions.
89% more capital invested
Capital invested by funds: $199M → $375M (+$176M)
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
0% more funds holding
Funds holding: 135 → 135 (0)
7% less call options, than puts
Call options by funds: $360K | Put options by funds: $388K
1.35% less ownership
Funds ownership: 93.58% → 92.23% (-1.3%)
15% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$9.07M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.81M |
| 3 |
Two Sigma Investments
New York
|
+$1.69M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.57M |
| 5 |
BlackRock
New York
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.03M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.61M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.43M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.36M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.27M |
MGNX Hedge Fund Activity: Q4 2022 in Review
135 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q4 2022, worth a combined $375M — up 89% from $199M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MGNX positions and 27 closed out — a net gain of 1 holder — while 41 added to existing stakes and 48 trimmed.
The largest buyer was Bellevue Group, adding an estimated $9.07M. The largest seller was Millennium Management, cutting an estimated $4.03M.
- 135 institutional investors held MacroGenics (MGNX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $375M of MacroGenics stock for Q4 2022, up 89% quarter-over-quarter.
- 28 funds opened new MacroGenics positions in Q4 2022 and 27 closed out, a net change of +1 holder.
- The largest MacroGenics buyer in Q4 2022 was Bellevue Group, an estimated $9.07M added.
- The largest MacroGenics seller in Q4 2022 was Millennium Management, an estimated $4.03M sold.
Based on aggregated 13F filings for Q4 2022.